Heron Therapeutics, Inc. (NASDAQ:HRTX) Stake Lessened by Two Sigma Investments LP

Two Sigma Investments LP lessened its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 29.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 990,169 shares of the biotechnology company's stock after selling 411,906 shares during the quarter. Two Sigma Investments LP owned about 0.65% of Heron Therapeutics worth $1,515,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Nicolet Advisory Services LLC acquired a new stake in shares of Heron Therapeutics in the 4th quarter valued at approximately $25,000. Argent Advisors Inc. acquired a new position in Heron Therapeutics during the fourth quarter worth $31,000. Focus Partners Wealth acquired a new position in Heron Therapeutics during the fourth quarter worth $31,000. State of Wyoming raised its holdings in shares of Heron Therapeutics by 573.5% in the fourth quarter. State of Wyoming now owns 29,736 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 25,321 shares during the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of Heron Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 33,063 shares of the biotechnology company's stock worth $51,000 after acquiring an additional 10,880 shares during the last quarter. Hedge funds and other institutional investors own 80.01% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HRTX. Needham & Company LLC reissued a "buy" rating and issued a $4.00 price target on shares of Heron Therapeutics in a report on Friday, April 11th. Wall Street Zen raised Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday.

Heron Therapeutics Stock Up 5.0%

Shares of NASDAQ HRTX traded up $0.10 on Friday, hitting $2.10. The company had a trading volume of 1,707,789 shares, compared to its average volume of 2,240,458. Heron Therapeutics, Inc. has a 12-month low of $1.04 and a 12-month high of $3.93. The business has a 50 day moving average of $2.02 and a two-hundred day moving average of $1.86. The firm has a market capitalization of $320.38 million, a P/E ratio of -11.67 and a beta of 1.15.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The firm had revenue of $38.90 million for the quarter, compared to analyst estimates of $37.08 million. On average, sell-side analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.